S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
AppLovin (APP): Losing its shareholders lovin'?
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
AppLovin (APP): Losing its shareholders lovin'?
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
AppLovin (APP): Losing its shareholders lovin'?
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
New CBOE “special perk” helps traders target income every weekend (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
AppLovin (APP): Losing its shareholders lovin'?

Arrowhead Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARWR)

$24.93
+1.76 (+7.60%)
(As of 12/4/2023 ET)
Compare
Today's Range
$23.20
$24.93
50-Day Range
$21.20
$29.12
52-Week Range
$20.67
$42.48
Volume
2.80 million shs
Average Volume
1.05 million shs
Market Capitalization
$2.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.00

Arrowhead Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
105.2% Upside
$51.15 Price Target
Short Interest
Bearish
7.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.55
Upright™ Environmental Score
News Sentiment
0.47mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$2.82 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.72) to ($2.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

492nd out of 952 stocks

Pharmaceutical Preparations Industry

232nd out of 434 stocks


ARWR stock logo

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

ARWR Stock Price History

ARWR Stock News Headlines

What 4 Analyst Ratings Have To Say About Arrowhead Pharma
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Call
3 Pharma Stocks on the Rise - It's Time to Buy Now
Citi Reaffirms Their Hold Rating on Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals: A High-Risk, High-Reward Bet
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2023
Today
12/04/2023
Next Earnings (Estimated)
2/05/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
397
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.15
High Stock Price Target
$90.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+112.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
15 Analysts

Profitability

Net Income
$-205,270,000.00
Pretax Margin
-85.78%

Debt

Sales & Book Value

Annual Sales
$240.74 million
Book Value
$2.68 per share

Miscellaneous

Free Float
102,060,000
Market Cap
$2.68 billion
Optionable
Optionable
Beta
0.78
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 54)
    CEO, President & Director
    Comp: $1.65M
  • Mr. Kenneth A. MyszkowskiMr. Kenneth A. Myszkowski (Age 57)
    Chief Financial Officer
    Comp: $761.55k
  • Mr. Patrick O'Brien J.D. (Age 59)
    PharmD, COO, General Counsel & Secretary
    Comp: $749.86k
  • Dr. James C. Hamilton M.D. (Age 45)
    MBA, Chief of Discovery & Translational Medicine
    Comp: $676.81k
  • Ms. Tracie OliverMs. Tracie Oliver
    Chief Commercial Officer
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Mark Seefeld (Age 69)
    Head of Toxicology & VP
  • Dr. Javier San Martin M.D. (Age 58)
    Chief Medical Officer
    Comp: $658.48k














ARWR Stock Analysis - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price target for 2024?

15 equities research analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' shares. Their ARWR share price targets range from $27.00 to $90.00. On average, they anticipate the company's share price to reach $51.15 in the next year. This suggests a possible upside of 105.2% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2023?

Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of 2023. Since then, ARWR shares have decreased by 38.5% and is now trading at $24.93.
View the best growth stocks for 2023 here
.

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 7,880,000 shares, an increase of 9.9% from the October 31st total of 7,170,000 shares. Based on an average daily trading volume, of 995,100 shares, the short-interest ratio is presently 7.9 days. Approximately 7.8% of the company's stock are short sold.
View Arrowhead Pharmaceuticals' Short Interest
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.38. The biotechnology company had revenue of $15.83 million for the quarter, compared to analyst estimates of $45.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 85.27%. Arrowhead Pharmaceuticals's revenue was down 51.2% on a year-over-year basis. During the same period last year, the firm earned ($0.68) earnings per share.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (4.02%), JPMorgan Chase & Co. (2.60%), Invesco Ltd. (2.28%), Northern Trust Corp (1.18%), Avidity Partners Management LP (0.99%) and Bank of New York Mellon Corp (0.92%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, Tracie Oliver, Victoria Vakiener and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ARWR) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -